493 related articles for article (PubMed ID: 22766314)
21. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
22. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
[TBL] [Abstract][Full Text] [Related]
23. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
25. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M
Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Di BS; Wei KP; Tian JH; Xiao XJ; Li Y; Zhang XH; Yu Q; Yang KH; Ge L; Huang WH; Zhang FW
Asian Pac J Cancer Prev; 2014; 15(8):3419-24. PubMed ID: 24870732
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
[TBL] [Abstract][Full Text] [Related]
31. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
[TBL] [Abstract][Full Text] [Related]
32. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Tiseo M
J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
[TBL] [Abstract][Full Text] [Related]
33. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Socinski MA; Raju RN; Stinchcombe T; Kocs DM; Couch LS; Barrera D; Rousey SR; Choksi JK; Jotte R; Patt DA; Periman PO; Schlossberg HR; Weissman CH; Wang Y; Asmar L; Pritchard S; Bromund J; Peng G; Treat J; Obasaju CK
J Thorac Oncol; 2010 Dec; 5(12):1963-9. PubMed ID: 21102260
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
Gervais R; Robinet G; Clément-Duchêne C; Denis F; El Kouri C; Martin P; Chouaki N; Bourayou N; Morère JF
Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
36. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
[TBL] [Abstract][Full Text] [Related]
37. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.
Chen YM; Shih JF; Fan WC; Wu CH; Chou KT; Tsai CM; Lee YC; Perng RP; Whang-Peng J
J Chin Med Assoc; 2011 May; 74(5):209-14. PubMed ID: 21550007
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
40. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
